Myriad Genetics (NASDAQ:MYGN) Given Daily News Sentiment Score of 0.13
News stories about Myriad Genetics (NASDAQ:MYGN) have been trending somewhat positive on Saturday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Myriad Genetics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.1430551674707 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Myriad Genetics, Inc. (NASDAQ:MYGN) Upgraded by BidaskClub to “Buy” (americanbankingnews.com)
- Myriad Genetics, Inc. – Value Analysis (NASDAQ:MYGN) : August 12, 2017 (finance.yahoo.com)
- Myriad Genetics, Inc. Expected to Post Q1 2018 Earnings of $0.21 Per Share (NASDAQ:MYGN) (americanbankingnews.com)
- Zacks Investment Research Lowers Myriad Genetics, Inc. (MYGN) to Hold (americanbankingnews.com)
- Uptrend Call Working As Myriad Genetics Stock Rises 30.2% (MYGN) (mysmartrend.com)
A number of analysts have issued reports on the company. BidaskClub raised Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday. Zacks Investment Research downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Myriad Genetics in a research note on Thursday. Barclays PLC reduced their price objective on Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $22.00 price objective on shares of Myriad Genetics in a research note on Friday, July 14th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. Myriad Genetics has a consensus rating of “Hold” and an average price target of $21.78.
Myriad Genetics (MYGN) traded up 2.06% during trading on Friday, hitting $27.76. The stock had a trading volume of 1,573,744 shares. The company’s 50 day moving average is $25.18 and its 200-day moving average is $20.92. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $28.39. The company has a market cap of $1.90 billion, a PE ratio of 87.02 and a beta of 0.31.
Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.04. The business had revenue of $200.50 million for the quarter, compared to the consensus estimate of $193.71 million. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.36 earnings per share. On average, equities research analysts predict that Myriad Genetics will post $1.05 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Myriad Genetics (NASDAQ:MYGN) Given Daily News Sentiment Score of 0.13” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/myriad-genetics-nasdaqmygn-given-daily-news-sentiment-score-of-0-13/1480029.html.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.